The fundamental purpose of Чарозетта (Desogestrel) is applied across domains where additional symptomatic support is needed in managing fertility. This is considered the main therapeutic domain. The medication is commonly used to help with the recurring monthly fertility potential and is relevant when supportive symptom management is appropriate in reproductive health.

Its use may be relevant for addressing the need for estrogen avoidance, supporting symptomatic management during the postpartum period for lactating women, and easing the symptom load related to menstrual bleeding. The medication is considered relevant when symptoms related to systemic imbalance linked to estrogen are a concern. This provides support that may help ease symptoms that interfere with daily functioning in these contexts.

“The medication is considered relevant for women seeking a hormonal method when estrogen-containing options are not suitable.”

---

Quick Fact: Relief for Estrogen Avoidance

The medication is considered relevant when symptoms related to systemic imbalance linked to estrogen are a concern, providing support that may assist with easing symptoms that interfere with daily functioning in these contexts.

Eligibility Map: Who Can and Cannot Use Чарозетта — Official Regulatory Information

---

Eligibility Scope

Classification	Rule Summary (Official Labeling)
Populations for whom use is allowed	Women of reproductive age, especially those requiring a progestogen-only method (e.g., while breastfeeding or when oestrogens are medically inappropriate).
Populations for whom use is not recommended	Prepubescent girls (before menarche) due to insufficient established safety data.
Populations for whom use is contraindicated	Women with active venous thromboembolic disorder (VTE); known or suspected sex-steroid sensitive malignancies (e.g., breast cancer); undiagnosed vaginal bleeding; or severe liver disease until liver function returns to normal.
Age-related eligibility rules	Approved for adults. Not indicated for post-menopausal women.
Condition-specific eligibility rules	Contraindicated in severe hepatic disease. No specific restrictions are documented for renal impairment.
Pregnancy and lactation eligibility status	Contraindicated during known or suspected pregnancy. Permitted for use while breastfeeding.
Eligibility-related restrictions	Women with a history of chloasma gravidarum should avoid sun or UV radiation.

---

Eligibility Classifications (High-Level)

Classification	Status Definition (Official Regulatory Documents)
Eligibility severity classification	Contraindicated; Permitted; Not Recommended.
Regulatory basis	Primarily European Medicines Agency (EMA) Summary of Product Characteristics (SmPC) and corresponding national prescribing information.
Eligibility-context constraints	The primary constraint is the need to avoid oestrogen-containing hormonal contraception.

---

Resulting Eligibility Structure

Official eligibility statements:

• Use is contraindicated in the presence of active VTE or sex-steroid sensitive malignancies.
• The medicine may be used by women who are breastfeeding.
• Use is not recommended before the onset of menstruation.

Connection to the overall eligibility profile: Official regulatory documents define the eligible population by establishing absolute contraindications concerning malignancy, thromboembolic risk, and severe liver impairment. The profile is strictly limited to women of reproductive age, is prohibited during pregnancy, but is explicitly permitted during lactation. The medicine is restricted to women whose clinical profile matches the officially established safety criteria.

The regulatory information for Чарозетта (Desogestrel) details specific pharmacokinetic interactions that affect the plasma concentrations of its active metabolite, Etonogestrel, or the clearance of co-administered substances. The primary interaction patterns are categorized by the influence on hepatic enzyme metabolism, mainly the Cytochrome P450 3A4 (CYP3A4) system.

Documented Interaction Patterns

Interaction Type	Interacting Substances	Official Outcome
Reduced Exposure (Enzyme Induction)	Anticonvulsants (e.g., Phenytoin, Carbamazepine, Phenobarbital), Anti-infectives (e.g., Rifampicin), St. John's Wort	These agents increase the clearance of Etonogestrel, leading to reduced plasma concentrations and the potential for a loss of efficacy.
Increased Exposure (Enzyme Inhibition)	Antifungals (e.g., Ketoconazole, Itraconazole), certain Antibiotics (e.g., Clarithromycin), Diltiazem	These agents inhibit the metabolism of Etonogestrel, resulting in increased systemic exposure.
Altered Clearance of Other Medicines	Ciclosporin, Lamotrigine	Exposure to Ciclosporin may be increased. Exposure to Lamotrigine may be reduced.

Interaction-Related Constraints

When co-administering any agent documented as an enzyme inducer, regulatory guidelines require the use of an additional barrier contraceptive method during the concurrent use and for a period extending 28 days after discontinuation of the interacting medicine. This mandatory measure addresses the sustained risk of reduced contraceptive effectiveness caused by the altered clearance of Etonogestrel. The interaction profile strictly focuses on these documented effects and the required compensatory precautions.

How Чарозетта Works

The drug’s action is defined by its layered mechanism, driven by the active metabolite Etonogestrel, which acts as a high-affinity Progesterone Receptor (PR) agonist, establishing three primary physiological actions.

---

Central Suppression of the Reproductive Cycle

This domain involves the drug's action on the central Hypothalamic-Pituitary-Ovarian (HPO) axis. Etonogestrel binds to the PR in the pituitary and hypothalamus, reinforcing the negative feedback loop that consistently suppresses the Luteinizing Hormone (LH) surge. This suppression arrests the final stages of follicular development, resulting in the inhibition of ovulation—the release of the egg.

---

Peripheral Barrier Mechanisms

This domain covers the local effects of Etonogestrel on the cervical mucus and the endometrial lining. The drug rapidly increases the viscosity of the cervical mucus, creating a dense, physical barrier that impedes sperm migration. Concurrently, it induces atrophy (thinning) in the endometrium, rendering the uterine lining structurally non-receptive to the attachment of a fertilized ovum.

---

Functional Constraint and Metabolic Integrity

Ovulation inhibition requires sustained, adequate plasma concentrations of Etonogestrel, which is subject to metabolic breakdown by the hepatic CYP3A4 enzyme system. Acceleration of this breakdown pathway by co-administered substances can lead to sub-therapeutic levels, resulting in a reduced capacity to sustain consistent central suppressive signaling.

How to Use Чарозетта (Desogestrel 75 mu g)

The administration of the desogestrel 75 mu g film-coated tablet follows a continuous, fixed-dose daily schedule. The medication is for oral use, and the regimen is distinct from combined pills as it involves taking active tablets every day without any hormone-free break.

---

Official Administration Guidelines

Instruction	Detail
Route and Dose	One 75 mu g desogestrel tablet is taken orally once daily.
Dosing Schedule	Continuous use is required; a new pack must be started immediately the day after the previous pack is finished, without interruption.
Timing and Intake	The tablet must be taken at about the same time each day, ensuring the interval between two tablets is consistently 24 hours. It can be taken with or without food, and should be swallowed whole with water.
Missed Dose Rule	A 12-hour threshold is used to manage delays. If the user is less than 12 hours late, the missed tablet must be taken immediately and the next one at the usual time, maintaining protection. If the delay exceeds 12 hours, a non-hormonal barrier method must be used for the next seven consecutive days.

---

Procedural Context

Specific protocols guide the initiation of use. For those starting without recent hormonal use, the first tablet should be taken on the first day of menstrual bleeding for immediate protection. For those switching from other hormonal methods, or starting post-partum or post-abortion, specific procedures must be followed to avoid a gap in coverage. If vomiting occurs within 3 to 4 hours of taking the tablet, the event must be treated as a missed dose, and a new tablet taken as soon as possible.

Research evidence / Overview of Studies for Чарозетта

Evidence for Use in Contraception (Prevention of Pregnancy)

The core research base for Чарозетта (desogestrel) draws upon Randomized Controlled Trials (RCTs), Multicenter Comparative Trials, and systematic reviews. These studies were conducted to examine the core clinical context the research examined: contraception in healthy, fertile women. Researchers studied the contraceptive efficacy outcome, measured by the Pearl Index. Trials also monitored the consistency of ovulation inhibition, a feature that researchers examined in comparison to older progestogen-only pills.

Pivotal studies also explored changes in vaginal bleeding patterns as a core outcome. Findings described patterns observed in the study groups, including instances where women reported having amenorrhea (absence of monthly bleeding) or, conversely, frequent or prolonged bleeding. A key limitation is that most pivotal trials for this class of medicine have follow-up durations that were limited to about one year.

---

Research in Postpartum and Lactating Women

Research has evaluated Чарозетта’s use in women who require contraception while breastfeeding. The evidence is drawn from systematic reviews that synthesize results from both non-randomized and observational studies. These studies explored if use of the pill was associated with any changes in lactation performance, such as the volume of milk produced or its composition.

Studies also monitored infant outcomes related to daily functioning, such as growth and development metrics. The research describes that most findings indicated no observed difference in the measured growth parameters of the infants studied when compared to control groups. This evidence contributes to the broader evidence landscape regarding the use of hormonal contraception during the postpartum period. However, the evidence quality varies across studies, and many are observational, meaning the certainty remains low for detailed, long-term assessments of development.

---

Studies for Use in Estrogen Avoidance

This medication was studied for women who are seeking hormonal contraception but have medical reasons or risk factors that make estrogen-containing options unsuitable—a group that requires estrogen avoidance. Research describes patterns that indicate the pill's utility in this context, based on study findings showing consistent ovulation suppression without the estrogen component. Studies reported that serum estradiol levels were measured and described as being reduced to a range comparable to the early follicular phase of the menstrual cycle.

---

Summary of Evidence Consistency and Gaps

The research provides insight into the patterns observed regarding contraceptive outcomes, where findings are largely consistent across trials. The most noted gap in the research relates to the issue of bleeding patterns, where reported outcomes show significant variability. Research describes that this pattern of variability is consistent across the research landscape. Limited information for long-term outcomes is a continuing gap, meaning data for continuation rates beyond the initial follow-up periods are limited compared to the initial short-term outcome data.

Key Studies & References

1. Maintenance of ovulation inhibition with the 75-microg desogestrel-only contraceptive pill (Cerazette) after scheduled 12-h delays in tablet intake (RCT/Multicenter Study)
2. Progestogen-only contraceptive use among breastfeeding women: a systematic review (CDC Stacks)

Common questions about Чарозетта (FAQ)

---

Q: Is Чарозетта a microdosed drug?

The medicine is a progestogen-only pill (POP) containing 75 mu g of desogestrel. This type of medicine is often referred to by patients and clinicians as a 'mini-pill.' While regulatory documents do not define 'microdosed,' the term historically distinguishes progestogen-only pills from combined pills.

---

Q: Does Чарозетта take effect immediately after starting?

Official administration guidelines state that if you start taking the first tablet on Day 1 of the menstrual bleeding, immediate contraceptive protection is described as achieved. If administration begins on days 2 through 5 of the menstrual cycle, a barrier method should be used additionally for the first seven days of tablet taking.

---

Q: Is additional contraception needed at the start?

Yes, regulatory product information advises that if the medicine is not started on Day 1 of the menstrual cycle, an additional non-hormonal barrier method is required according to official guidelines. This supplementary method must be used for the first seven consecutive days of tablet-taking.

---

Q: Can Чарозетта cause weight gain?

Official regulatory documents list weight increase as a common undesirable effect associated with this medicine. This means it may affect up to 1 in 10 people who use the medication.

---

Q: Is it true that Чарозетта can affect mood?

Yes, official product information includes mood changes and depressed mood/depression as documented undesirable effects. Official information suggests consulting a healthcare provider in case of mood changes or depressive symptoms, including shortly after initiation of treatment.

---

Q: Can Чарозетта be taken while breastfeeding?

Regulatory documents state that this medicine is permitted for use while a woman is breastfeeding. A small amount of the active metabolite, etonogestrel, is known to pass into the breast milk.

---

Q: Do antibiotics affect the action of Чарозетта?

The official interactions list specifies that certain anti-infective medicines, particularly Rifampicin and Rifabutin, are strong enzyme inducers that can significantly reduce efficacy. For common antibiotics, no interaction reducing efficacy is typically listed, but specific warnings apply to enzyme inducers.

---

Q: What is the difference between Чарозетта and other desogestrel preparations?

The core component, desogestrel 75 mu g, is the same across different commercially available preparations. The primary differences between products with the same active dose relate to the commercial name, inactive ingredients, and manufacturer.

---

Q: Why can irregular bleeding occur with Чарозетта?

Irregular bleeding, including frequent, prolonged, or absent bleeding, is listed as a very common side effect. This is a result of the medicine's progestogenic influence on the lining of the womb (the endometrium) as part of its mechanism.

---

Q: How does Чарозетта affect the skin and acne?

Official product information lists acne as a common undesirable effect, meaning it may appear or worsen during use of the medicine.

---

Q: Is there a risk of thrombosis with Чарозетта?

Yes, the official warnings state that the medicine carries a documented risk of Venous Thromboembolism (VTE). For this safety reason, the use of the medicine is contraindicated in women with an active thromboembolic disorder.

---

Q: Is Чарозетта suitable for women aged 40+?

The medicine is indicated for contraception in women of reproductive age. The medicine is used for women who require estrogen avoidance, which may include women in this age group who have medical reasons to avoid estrogen-containing contraceptives. No special dosage instructions are given for this age group.

---

Q: Are special tests needed before starting Чарозетта?

Official guidelines advise that a medical history and physical examination take place before starting the medication. Specific ongoing monitoring is noted for certain pre-existing conditions, such as Diabetes Mellitus.

---

Q: Why doesn't Чарозетта contain estrogen?

The medicine is specifically formulated as a progestogen-only pill (POP) to be suitable for women who have medical reasons or contraindications to estrogens. This feature makes it an option for women who are breastfeeding or those with certain cardiovascular risk factors.

---

Q: Does Чарозетта affect blood test results?

Official warnings state that treatment with desogestrel can lead to decreased serum levels of estradiol (an estrogen hormone). Additionally, the medicine can affect the clearance of other specific medications, such as Lamotrigine and Ciclosporin, which may be reflected in blood tests.

---

Q: Is there data on the use of Чарозетта in women with Diabetes Mellitus?

The official product information notes that specific monitoring is required for women with Diabetes Mellitus. However, the regulatory guidance indicates that there is no consistent evidence to show a need to alter the diabetes therapeutic regimen in women using progestogen-only pills.

Storage and Disposal of Cerazette (Чарозетта)

The medicine must be stored at a temperature not exceeding 30 C. To maintain its integrity, the blister pack must be kept in the original sachet to provide protection from both light and moisture.

Once the original sachet is opened for the first time, the tablets must be used within one month. The product must be stored securely out of the sight and reach of children.

Disposal of any unused or expired tablets must be completed in accordance with local requirements. Regulatory information notes that the active metabolite presents an environmental risk to fish, indicating that disposal should avoid wastewater or other direct environmental release.